Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-55

'The markets are not terribly efficient in the short term but they are in the long term'. Very true.

What we're seeing with BOT is classic biotech. There's promise showing that BOT will, at some point, deliver goods which will provide a significant return. But we're not there yet. Yesterday's news was really encouraging, hence the 10-15% price increase, but there is still a ways to go. I still think we will see BOT creep up into the teens and maybe into the 20c's before year's end, but no more until either the market overcomes current fears and/or we can 'guarantee' a return, either from SB sales occurring or Acne successfully completing Phase 3.

It's not for everybody, but to me all the indicators are that patience will highly likely pay off, soon enough (and by soon I mean late 2023).